Kyverna Therapeutics (KYTX) Current Assets (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Current Assets data on file, last reported at $241.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 2.39% year-over-year to $241.7 million; the trailing twelve-month figure through Mar 2026 stood at $241.7 million (down 2.39% YoY), and the FY2025 full-year result was $283.0 million, down 2.63% from the prior year.
• Current Assets for Q1 2026 stood at $241.7 million, down from $283.0 million in the prior quarter.
• Across five years, Current Assets topped out at $375.5 million in Q1 2024 and bottomed at $60.7 million in Q4 2023.
• The 4-year median for Current Assets is $265.3 million (2025), against an average of $256.3 million.
• The widest annual swing landed in 2024, when Current Assets jumped 379.03%; it then sank 46.24% in 2025.
• A 4-year view of Current Assets shows it stood at $60.7 million in 2023, then soared by 379.03% to $290.6 million in 2024, then declined by 2.63% to $283.0 million in 2025, then dropped by 14.57% to $241.7 million in 2026.
• The last three Current Assets figures came in at $241.7 million (Q1 2026), $283.0 million (Q4 2025), and $174.9 million (Q3 2025), per Business Quant data.

Peer Comparison